The resistance story: how gonorrhea defeated nearly every antibiotic
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Gonorrhea has beaten every class of antibiotic ever used against it, usually within a decade or two. For several years, ceftriaxone by injection was the only recommended treatment left anywhere.
In December 2025 that changed. Here is how the field got to this point and where it stands now.
Related pages: Gonorrhea
The bottom line
- N. gonorrhoeae takes up loose DNA from its environment, including resistance genes from harmless relatives in the throat.
- Sulfonamides, penicillin, tetracyclines, ciprofloxacin and azithromycin have all been lost in turn.
- The current first-line treatment is a single 500 mg injection of ceftriaxone.
- In December 2025 the FDA approved two new oral antibiotics, gepotidacin and zoliflodacin.
- How long the new drugs will last before resistance appears.
- Whether they will work well enough for throat infections, where they aren't approved.
The story, step by step
- 1. Why it adapts ()
- 2. 1930s to 1980s ()
- 3. 1990s to 2010s (US surveillance programs and others)
- 4. The last line (National surveillance programs)
- 5. December 2025 (GSK (gepotidacin) and Entasis (zoliflodacin))
- 6. What it means for you ()
What the evidence labels mean
A bacterium that picks up DNA off the floor
What happens
N. gonorrhoeae is naturally competent, meaning it takes up loose DNA from its surroundings and stitches useful pieces into its own genome.
What the research shows
- Harmless Neisseria species live in most people's throats, and they share DNA with the gonococcus.
- Those relatives are exposed to every antibiotic a person ever takes, for any reason, and accumulate resistance genes.
- A throat gonorrhea infection sits right in that pool, which is why the throat is called a resistance reservoir.
- On top of this, ordinary mutations in the bacterium's own genes contribute resistance.
Why it matters
This isn't bad luck. It's a bacterium built to acquire other organisms' solutions, living in the one place where those solutions accumulate.
What's still uncertain
- How much resistance comes from gene transfer versus mutation differs by drug class.
Read more
- CDC: Drug-resistant gonorrheaGovernment
- OwieClear: How gonorrhea invades the liningsOwieClear
Next: 1930s to 1980s
Sulfa drugs, then penicillin, then tetracycline
What happens
Each new class was introduced with confidence and lost within years to decades.
What the research shows
- Sulfonamides arrived in the 1930s and resistance emerged within about a decade.
- Penicillin replaced them in the 1940s. Doses had to be raised repeatedly as sensitivity fell.
- In the 1970s and 1980s, strains appeared carrying plasmids with beta-lactamase, an enzyme that chemically destroys penicillin.
- Tetracyclines went the same way.
Why it matters
The pattern was established early: effective drug, rising doses, then abandonment.
What's still uncertain
- Exact timelines differ between countries, and resistance often appeared in some regions long before others.
Read more
- CDC: Drug-resistant gonorrheaGovernment
Next: 1990s to 2010s
Ciprofloxacin, then azithromycin
What happens
Fluoroquinolones such as ciprofloxacin became standard in the 1990s because they were oral, cheap and effective.
What the research shows
- Mutations in the bacterium's DNA-gyrase enzyme made them fail, and in 2007 US guidance stopped recommending them.
- That left cephalosporins as the only recommended class.
- To protect them, guidance moved to dual therapy: a ceftriaxone injection plus oral azithromycin.
- Azithromycin resistance then rose, and in December 2020 US guidance dropped it, returning to ceftriaxone alone, at a higher 500 mg dose.
Why it matters
Dual therapy was a deliberate attempt to slow resistance. It bought about a decade.
What's still uncertain
- Whether dropping azithromycin was the right call is still discussed among specialists.
Read more
- CDC: Drug-resistant gonorrheaGovernment
- CDC MMWR: update to gonorrhea treatment recommendationsGovernment
Next: The last line
Ceftriaxone alone, and the strains that beat it
What happens
For several years a single injection of ceftriaxone was the only recommended treatment in most countries.
What the research shows
- The dose is 500 mg into a muscle for most people, or 1 g for people weighing 150 kg or more.
- It covers urethral, cervical, rectal and throat infections.
- Strains with reduced susceptibility to ceftriaxone, and some fully resistant, have been found in several countries and have reached the United States.
- Canada's surveillance identified 13 ceftriaxone-resistant cases between 2017 and 2024, which gives a sense of how rare but real this is.
- Throat infections are hardest to clear, which is why a follow-up test is recommended for them.
Why it matters
Resistant cases are still rare, and most people are cured by the standard shot. But the margin had become uncomfortably thin.
What's still uncertain
- Surveillance is patchy worldwide, so true rates are unknown in many countries.
Read more
- Public Health Agency of Canada: gonorrhea treatment and resistance surveillanceGovernment
- CDC: Drug-resistant gonorrheaGovernment
Next: December 2025
Two new oral antibiotics, the first new class in decades
What happens
Both drugs block bacterial DNA replication at binding sites different from existing antibiotics, so existing resistance doesn't apply.
What the research shows
- Gepotidacin (Blujepa) was approved on 11 December 2025 for uncomplicated urogenital gonorrhea in people aged 12 and over. In the EAGLE-1 trial, two oral 3,000 mg doses cured 92.6% of urogenital infections against 91.2% for the injection plus azithromycin.
- Zoliflodacin (Nuzolvence) was approved the next day. In its phase 3 trial of 930 people, a single oral dose cured 90.9% against 96.2% for the standard combination.
- Both are approved only for uncomplicated urogenital infection, not rectal or throat infection.
- Both are intended for people with limited treatment options, not as a general replacement for the injection.
Why it matters
After decades with the pipeline nearly empty, there are now oral options that work against resistant strains. The injection remains the standard first-line treatment.
What's still uncertain
- Safety data in wider use is still limited, which is why health departments are restricting them.
- Not being approved for throat infection matters, because that is where resistance develops.
- Resistance to these will eventually appear. The history on this page is the reason to assume so.
Read more
- Ross 2025, The Lancet: EAGLE-1 trial of oral gepotidacinJournal
- CIDRAP: FDA approves 2 new oral gonorrhea antibioticsUniversity
Next: What it means for you
What this changes for someone being treated
What happens
Translating all of this into practice.
What the research shows
- The injection is still what almost everyone will be given, and it still works for almost everyone.
- Finish the whole treatment, and never use leftover or shared antibiotics. Partial treatment is exactly how resistance is bred.
- Come back if symptoms don't settle within a few days. That can be a sign of a resistant strain and is worth culturing.
- A throat infection needs a follow-up test about 1 to 2 weeks after treatment.
- Getting partners treated prevents reinfection and limits how much the bacterium circulates and swaps genes.
Why it matters
The individual advice and the global resistance problem are the same advice. Taking treatment properly is a public act as much as a personal one.
Read more
- CDC: About gonorrheaGovernment
- OwieClear: Recovering from gonorrheaOwieClear